Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193245 · ClinicalTrials.gov registry record · Phase 2
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00193245 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 80 participants.
The verdict
NCT00193245, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.
Interventions
- DRUG Docetaxel
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2000-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193245
The ClinicalTrials.gov registry entry for NCT00193245 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00193245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193245 about?
NCT00193245 is a clinical study titled "Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer". In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.
What is the current status of trial NCT00193245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2000-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00193245?
The interventions under investigation include: Docetaxel (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT00193245?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.